Page last updated: 2024-12-09
jpm 565
Description
JPM 565: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (9)
| Synonym |
|---|
| oxiranecarboxylic acid, 3-[[[(1s)-1-[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-, ethyl ester, (2s,3s)- (9ci) |
| 2-oxiranecarboxylic acid, 3-[[[(1s,2s)-1-[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-2-methylbutyl]amino]carbonyl]-, ethyl ester, (2s,3s)- |
| cid644294 |
| ethyl (2s,3s)-3-[[(2s)-1-[2-(4-hydroxyphenyl)ethylamino]-3-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate |
| CHEMBL1242843 |
| jpm 565 |
| bdbm36334 |
| 3-(ethoxycarbonyl)-n-(1-hydroxy-1-{[2-(4-hydroxyphenyl)ethyl]imino}-3-methylpentan-2-yl)oxirane-2-carboximidic acid |
| DTXSID00949102 |
Protein Targets (4)
Inhibition Measurements
Ceullar Components (1)
| Process | via Protein(s) | Taxonomy |
|---|
| cytosol | Caspase-3 | Mus musculus (house mouse) |
| [Information is prepared from geneontology information from the June-17-2024 release] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.24
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.24 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |